Skip to main content

Advertisement

Table 6 Hypothetical 95% CIs around different rivaroxaban–standard anticoagulation hazard ratio assumptions

From: Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study

Assumed rivaroxaban–standard anticoagulation hazard ratio Assumed 95% CI if incidence of the main efficacy outcome is 2.0% on standard anticoagulationa Assumed 95% CI if incidence of the secondary efficacy outcome is 10% on standard anticoagulationa
0.500 0.11–2.28 0.25–0.99
0.667 0.16–2.76 0.35–1.26
0.800 0.20–3.14 0.43–1.48
0.930 0.25–3.52 0.51–1.69
1.000 0.27–3.72 0.56–1.80
1.075 0.29–3.94 0.60–1.92
1.250 0.35–4.45 0.71–2.21
1.500 0.43–5.18 0.86–2.61
2.000 0.60–6.64 1.17–3.42
  1. Hypothetical 95% CIs around various hazard ratios assuming an incidence of 2.0% for the main efficacy outcome and 10% for the secondary efficacy outcome in the standard anticoagulation group in a population of 500 children randomized to rivaroxaban or standard anticoagulation in a 2 to 1 fashion. aBased on approximation, CI, confidence intervals